GlassScriptPhysician profile
Thomas Abraham Samuel
NPI 1831187947
$1,987.50
in general payments reported to CMS, 2019-2025
33 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.00 · 2020: $18.54 · 2021: $174 · 2022: $267 · 2023: $579 · 2024: $454 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $318.03 | 2019-2024 | Imbruvica, Darzalex, Tecvayli |
| Pfizer INC. | $285.82 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $165.56 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $139.00 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Taiho Oncology, INC. | $134.65 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $101.31 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.50 | 2023-2025 | Ninlaro, Vpriv, Iclusig |
| Daiichi Sankyo INC. | $68.32 | 2023-2025 | Enhertu |
| Eisai INC. | $63.00 | 2022-2024 | |
| Genentech USA, INC. | $61.17 | 2022-2024 | Phesgo, Tecentriq Hybreza, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $58.22 | 2023-2024 | Enhertu |
| Genentech, INC. | $43.90 | 2023-2024 | Tecentriq |
| Genzyme Corporation | $43.90 | 2025 | |
| Coastal Medical Technologies LLC | $37.77 | 2023 | |
| Incyte Corporation | $36.07 | 2024 | Monjuvi, Pemazyre, Jakafi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.44 | 2022-2023 | Xtandi |
| Puma Biotechnology, INC. | $31.23 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $28.42 | 2025 | Monoferric |
| Abbvie INC. | $27.19 | 2025 | |
| Amgen INC. | $24.37 | 2021 | |
| Deciphera Pharmaceuticals INC. | $22.07 | 2024 | Qinlock |
| Tempus Ai, INC | $21.22 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Epkinly, Imbruvica |
| Immunogen, INC. | $20.71 | 2023 | Elahere |
| Seagen INC. | $19.80 | 2023 | Tivdak |
| Lilly USA, LLC | $18.10 | 2023 | Verzenio, Jaypirca |
| G1 Therapeutics, INC. | $17.25 | 2023 | Cosela |
| Sobi, INC | $17.21 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.65 | 2023 | |
| Iovance Biotherapeutics, INC. | $15.01 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $13.86 | 2024 | Orserdu |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.